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Abstract—Acylation of antimalarial and bacteriostatic sulfonamides with N-protected amino acids and peptides was carried out using
standard peptide coupling methods. These acylation reactions are regioselective for the N 4 nitrogen atom of diazine-containing
sulfonamides. In contrast, only N 1 coupling was found for sulfisoxazole, an isoxazole-based sulfonamide. Computational studies suggest that
a combination of geometrical, thermodynamic and electronic factors are responsible for the different reactivities reported.
q 2003 Elsevier Ltd. All rights reserved.
1. Introduction
Prodrug synthesis is a widely used strategy to improve the
delivery of drugs to their site of therapeutic action.1 The
most important application of the prodrug strategy is the
increase of the oral bioavailability of poorly absorbed
drugs.2 Prodrugs can release the parent drug either by
chemical or enzymatic activation. Although enzymatic
activation is preferred when the objective is site-specific
drug delivery (e.g. by designing a prodrug that is selectively
activated by a specific enzyme3), chemical prodrug
activation has the advantage of not being affected by
biological variability.4 A major requirement for any pro-
drug is the quantitative formation of the parent drug. This
objective can be easily achieved by taking the advantage of
facile intramolecular cyclization reactions.5 – 7
Although sulfonamides are best known as bacteriostatic8
and antimalarial agents,9 there is now a range of drugs,
possessing very different pharmacological activities, in
which the sulfonamide group is present.10 Several of these
drugs suffer from bioavailability problems or adverse
secondary effects.11 – 13 The prodrug strategy has been
widely used for solving biopharmaceutical problems of
this nature. Although several prodrugs have been specifi-
cally developed for sulfonamide agents, only few have
displayed adequate chemical and/or enzymatic activation
rates.14 – 17 The main interest of our research team concerns
the development of intramolecular cyclization-activated
prodrugs for antimalarial sulfonamides as potential
long-acting agents useful against chloroquine-resistant
Plasmodium falciparum strains. Our target molecules
involve drug modification with dipeptide carriers that can
release the parent drug through a non-enzymatic mecha-
nism, i.e. intramolecular cyclization to a 2,5-diketopiper-
azine.18,19 The dipeptide carrier can be linked to the
sulfonamide either via the 4-anilino group (N 4 nitrogen
atom), i.e. 1, or via the sulfonamido group (N 1 nitrogen
atom), i.e. 2 (Fig. 1). The corresponding prodrugs are
expected to undergo cyclization at significantly different
rates due to the large differences in the leaving group
abilities of the anilino and sulfonamido groups. We set out
to use classical peptide synthetic reactions to prepare
compounds 1 and 2. However, as described in the present
paper, we observed that sulfonamides are invariably
acylated at N 4 in a regioselective fashion. This contrasts
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sharply with reaction with other acylating agents, such as
acetic anhydride, which can lead to N 1 and N 4 acylation. To
obtain more information about the coupling reactions of
sulfonamides with amino acids and dipeptides, we took
advantage of recent advances in computational chemistry.
Density Functional Theory, DFT, has been applied
successfully in several fields of knowledge due to its ability
to predict geometrical and energetic values, which compare
excellently with experimental data. In the present work,
DFT calculations, carried out at the B3LYP/6-311þG**//
B3LYP/6-31G* level of theory, on the possible acylation
products from reaction of the four sulfonamides with amino
acid glycine have provided a possible explanation for our
experimental findings. The degree of N 1 or N 4 acylation is
shown to be governed by relative energetics of the reaction
products.
2. Results and discussion
2.1. Acylation of sulfonamides with protected amino
acids and dipeptides
All syntheses were based in standard peptide coupling
methods20 and involved N a-protected amino acid coupling
to the sulfa drug, using DCCI,21 HBTU/DIEA,22,23 Ph3P/
CCl4
24 in combination with the auxiliary nucleophiles
HOBt,25,26 DMAP.27
Since we were equally interested in both N 1 and N 4
acylated sulfonamides, we devised synthetic strategies in
order to favor the formation of either one or the other
monoacyl derivative. Thus, we assayed different synthetic
routes using sulfamethazine and N a-protected glycine as
the acylating agent. Regardless of the strategy employed, we
consistently obtained only one monoacylation product
(Table 1, entries A, B, S and T), which was found to be
the N 4-acyl derivative by NMR spectroscopy (absence of
the sulfamethazine Ar-NH2 peak, replaced by a new NH
signal at ca. 10 ppm). The lack of reactivity of N 4-
acetylsulfamethazine further confirmed that coupling at
N 4 is the favored acylation pathway (Table 1, entries U
and V).
Regioselective acylation at the N 4 atom was consistently
observed for other N a-protected amino acids and dipeptides
(Table 1, entries C – G), as well as for other two
sulfonamides, namely, sulfadimethoxine and sulfamethoxy-
pyridazine (Table 1, entries H–O). These share with
sulfamethazine the presence of a diazine ring linked to the
sulfonamido group (Fig. 1).
Despite the results described in the previous section, when
we stepped forward to sulfisoxazole, a sulfonamide that
contains an isoxazole instead of a diazine ring (Fig. 1), we
found that this drug was almost non-reactive in terms of
acylation with amino acids and dipeptides. Irrespective of
synthetic method employed, we obtained high recovery
levels of the parent drug ($70% of initial amount) together
with complex and intractable reaction mixtures (Table 1,
entries P and Q). The complexity of crude mixtures,
together with the low extension of sulfisoxazole conversion,
Figure 1. Dipeptide carriers in sulfonamide prodrugs: drug release by intramolecular cyclization with 2,5-diketopiperazine formation.
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disabled us to isolate the putative acylsulfisoxazoles, except
for one single case in which a few milligrams of one product
were isolated (Table 1, entry R) and characterized by NMR
spectroscopy as corresponding to the N 1-acyl derivative (no
signals were seen above 8 ppm and the sulfonamide Ar-NH2
protons were observed at 6.54 ppm).
To confirm that sulfisoxazole could be acylated at either
the N 1 and the N 4 atoms by other acylating agents, we
prepared N 1-acetyl, N 4-acetyl and N 1,N 4-diacetylsulfis-
oxazole with very good yields (data not shown), based
on methods described in the literature. We then tried to
force acylation of the N 1- and N 4-monoacetylsulfisox-
azoles prepared with N a-protected glycine, by three
different coupling methods. Again, all these assays were
unsuccessful and no products could be isolated (Table 1,
entries W–B0).
The results presented in Table 1 suggest that the site of
acylation with amino acids and dipeptides is independent of
either coupling method or solvent employed, and these two
factors affected only the synthesis yield. Thus, we decided
to search for a rational explanation for these experimental
findings, through computational chemistry calculations on
the possible acylation products of the four sulfonamides
when reacted with glycine. In this context, and as described
in the following sections, we started with molecular
geometry optimization for both reactants and products,
and then we stepped forward to the theoretical analysis of
the reaction energetics. The occupancy of the lone-pair in
sulfonamide N 1 and N 4 atoms, based on Natural Bond
Orbital (NBO) analysis, was also calculated.
2.2. Molecular structures
Relevant geometrical parameters of the reactants and their
N-acyl derivatives were obtained at the B3LYP/6-31G(d)
level of theory. These optimized structures were reached
by performing a full-optimization without symmetry
constraints. Analyzing the bond distances of atoms directly
bonded to sulfur it is shown that there are not appreciable
differences in the sulfur–oxygen bond lengths. The values
obtained negligibly differ from those described in a previous
work concerning the HS(O2)NH2 sulfonamide, 1.462 A˚.
28
However, when we turn our attention to what happens with
the S–N bonds in each species considered in the present
work, it is clear that this bond is rather elongated, by a
maximum of 0.06 A˚, when compared with the computed
S–N bond in HS(O2)NH2.
28 Bharatam et al. have computed
for the most stable HS(O2)NH2 isomer a S–N distance of
1.667 A˚ or 1.682 A˚ by employing the MP2/6-31þG*
and B3LYP/6-31þG* approaches, respectively. These
differences may be attributed to stereoelectronic effects
due to the presence of two aromatic rings, which comes into
agreement with previous findings of Bharatam et al.
describing the increase of the S–N bond length with an
increase in the electron donating nature of X in
XS(O)2NH2.
28 In fact, using B3LYP/6-31þG*, we have
calculated a S–N bond distance of 1.692 A˚ for the
PhS(O2)NH2 species, confirming the S–N elongation effect
of an aromatic ring bonded to the sulfur atom. This value for
PhS(O2)NH2 is now only 0.2 A˚ shorter than the computed
S–N lengths for compounds 3a–3c, but still 0.4 A˚ shorter
than for compound 3d (Fig. 2). In the latter compound, the
larger S–N bond length is due to a higher distortion of the
Table 1. Amino acid and dipeptide coupling reactions
Entry Sulfonamide Amino acid/dipeptide Coupling method Acylation product isolated; yield
A 3a BocGlyOH DCCI N 4-BocGlySulfamethazine (5a); 52%
B 3a ZGlyOH DCCI N 4-ZGlySulfamethazine (6a); 41%
C 3a BocAlaOH DCCI N 4-BocAlaSulfamethazine (7a); 49%
D 3a BocPheOH DCCI N 4-BocPheSulfamethazine (8a); 56%
E 3a BocGlyGlyOH DCCI N 4-BocGlyGlySulfamethazine (9a); 20%
F 3a BocAlaGlyOH DCCI N 4-BocAlaGlySulfamethazine (10a); 26%
G 3a BocPheGlyOH DCCI N 4-BocPheGlySulfamethazine (11a); 27%
H 3b BocGlyOH DCCI N 4-BocGlySulfadimethoxine (5b); 41%
I 3b BocGlyGlyOH DCCI N 4-BocGlyGlySulfadimethoxine (6b); 55%
J 3b BocAlaGlyOH DCCI N 4-BocAlaGlySulfadimethoxine (7b); 56%
K 3b BocPheGlyOH DCCI N 4-BocPheGlySulfadimethoxine (8b); 52%
L 3c BocGlyOH DCCI N 4-BocGlySulfamethoxypyridazine (5c); 43%
M 3c BocGlyGlyOH DCCI N 4-BocGlyGlymethoxypyridazine (6c); 37%
N 3c BocAlaGlyOH DCCI N 4-BocAlaGlySulfamethoxypyridazine (7c); 60%
O 3c BocPheGlyOH DCCI N 4-BocPheGlySulfamethoxypyridazine (8c); 52%
P 3d BocAAOH DCCI a
Q 3d ZAAOH (AA–Gly) DCCI a
R 3d ZGlyOH DCCI N 1-ZGlySulfisoxazole (5d); 8%
S 3a, sodium salt BocGlyOH DCCI N 4-BocGlySulfamethazine (5a); 38%
T 3a, sodium salt ZGlyOH DCCI N 4-ZGlySulfamethazine (6a); 32%
U N 4-acetylsulfamethazine BocGlyOH DCCI b
V N 4-acetylsulfamethazine BocGlyOH HBTU/DIEA b
W N 4-acetylsulfisoxazole BocGlyOH DCCI a
Y N 4-acetylsulfisoxazole BocGlyOH HBTU/DIEA a
X N 4-acetylsulfisoxazole BocGlyOH Ph3P/CCl4
a
Z N 1-acetylsulfisoxazole BocGlyOH DCCI a,c
A0 N 1-acetylsulfisoxazole BocGlyOH HBTU/DIEA a
B0 N 1-acetylsulfisoxazole BocGlyOH Ph3P/CCl4 a
a Intractable mixture—no products isolated; high recovery levels of starting materials.
b No products; full recovery of starting materials.
c N 1-deacetylation occurred when the DMAP catalyst was used together with DCCI.
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sulfonamide by a stronger pyramidalization at the N atom
(the S–N–C5 angle decreases by 58). The larger S–N and
A–B distances and the higher dihedral A–N–C5–B angle
observed for compound 3d contribute to a greater exposure
of the –SO2NH– group, eventually favoring the approach
of the acylation agent.
2.3. Energetics of acylation reactions
The enthalpies of the reactions of sulfonamides 3a–d with
glycine, considering acylation at either the N 1 or the N 4
position, were calculated using the H298.15 K values reported as
Supplementary Data, and the final results are given in Table 2.
From the results herewith reported it is noticed that the
reaction is always endothermic. The calculated enthalpies of
reaction fall in the 26–76 kJ mol21 interval and it is
interesting to note that acylation at N 4 is preferred. The
largest difference in enthalpies of reaction between acylation
at N 4 and N 1 is found for 3a while the smallest energetic
difference was calculated for 3d. Since the reactant and
product geometries are similar in reactions a to h, please see
Table 2 and geometric parameters given as Supplementary
Data, we may argue that the influence of the solvent will be
almost the same for these species. Therefore, the enthalpic
differences computed in the gas-phase may be used to extract
information about the reaction profiles in solution. Thus, it is
concluded that reaction at N 4 position is clearly preferred for
3a–c while for 3d, with an enthalpy difference of only
2.8 kJ mol21, acylation at the sulfonamido or the anilino
group should occur with equal probability. This could explain
both the experimental identification of an N 1-acylsulfizox-
azole and the complexity of crude mixtures in sulfisoxazole
reactions, possibly due to parallel formation of N 1-acyl, N 4-
acyl and even N 1,N 4-di-acylsulfisoxazoles.
2.4. Lone-pair occupancy in N 1 and N 4 as determined by
NBO analysis
Occupancies of the sulfonamide N 1 or N 4 lone pairs were
extracted from NBO analysis,29 and are shown in Table 3.
From this analysis, the following should be pointed out.
First, the occupancy of the lone pair in N 1 atoms is clearly
higher for sulfisoxazole, both in neutral and anionic forms.
Second, the N 1-anionic form presents a significantly lower
lone-pair occupancy when compared with the neutral form.
Third, the occupancies of the N 4 lone pairs are similar for
the four sulfonamides.
These results are consistent with the fact that only the
coupling reaction of sulfisoxazole with a protected amino
acid led to the isolation of an N 1-acyl derivative. Moreover,
the results also suggest that using sulfonamide N 1-con-
jugated bases will not increase the availability of the N 1
lone pair to react with acylating agents. Indeed, we were not
able to prepare any N 1-acyl derivatives using sulfonamide
sodium salts as starting reagents.
3. Conclusions
Taken together, our results are clear evidence that amino
acids, unlike other acyl reagents (e.g. Ac2O), are selective
sulfonamide acylating agents. This selectivity is not
influenced by the coupling method employed and is
reflected in the regioselective attack of amino acids and
dipeptides to the anilino group (N 4) of diazine-containing
sulfas, as well as in the completely different behavior
towards different types (diazine vs isoxazole) of sulfona-
mides. From what is above exposed, our experimental
findings seem to be explainable if we consider a
combination of geometrical, thermodynamic and electronic
factors. The results herein reported suggest that coupling
amino acids and dipeptides to the sulfonamide N 1 atom is
not feasible using standard peptide coupling chemistry and
thus new procedures should be devised.
4. Materials and methods
4.1. General details
N a-Protected amino acids and dipeptides were purchased
Figure 2. Atom numbering scheme used to define bond lengths and angles
reported as Supplementary Data. For simplicity, only part of the molecular
structure is shown; (A) is hydrogen or carbon, (B) is nitrogen or oxygen and
(C) is nitrogen or carbon.
Table 2. Enthalpies of reaction between sulfanilamides 3a–d and glycine
at both positions N 1 or N 4 computed at the B3LYP/6-311þG**//B3LYP/
6-31G* level of theory
Reaction DH298.15 K, (kJ mol
21)
(a) 3aþglycine!3aN1þH2O 76.1
(b) 3aþglycine!3aN4þH2O 26.0
(c) 3bþglycine!3bN1þH2O 68.5
(d) 3bþglycine!3bN4þH2O 28.8
(e) 3cþglycine!3cN1þH2O 50.3
(f) 3cþglycine!3cN4þH2O 37.5
(g) 3dþglycine!3dN1þH2O 34.4
(h) 3dþglycine!3dN4þH2O 31.6
Table 3. Lone pair occupancy in sulfonamide N 1 and N 4 atoms, based in a
Natural Bond Orbital analysis
Compound N 1 N 4 (neutral)
Neutral Anionic
3a 1.787 1.554 1.824
3b 1.796 1.570 1.816
3c 1.836 1.617 1.816
3d 1.861 1.665 1.815
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from NovaBiochem (Switzerland) and Bachem (Switzer-
land), respectively. Solvents were all of p.a. quality and
bought to Merck (Germany). Thin layer chromatography
glass plates, covered with silica 60 F254 (0.25 mm), and
silica-gel 60 (70–230 mesh ASTM) for preparative column
chromatography were also from Merck. When required,
solvents were previously dried with pre-activated molecular
sieves (4 A˚), equally bought to Merck. Other chemicals
were from Sigma-Aldrich.
NMR spectra of compounds solubilized in hexadeuterated
dimethyl sulfoxide (DMSO-d6), adding tetramethylsilane
(TMS) as internal reference, were acquired on a Bru¨cker
AC200 spectrometer. Mass spectrometry (MS) was per-
formed by the matrix-assisted laser desorption ionization-
time-of-flight (MALDI-TOF) technique on a Finnigan MAT
Lasermat 2000, using 2,5-dihydroxibenzoic acid (DHB) as
adjuvant matrix.
Synthetic details are described only for reactions that led to
novel sulfonamide derivatives in higher yields. Generally,
N-acylsulfonamides were prepared by condensation
with amino acids or dipeptides, using classical peptide
chemistry.20 Thus, dicyclohexylcarbodiimide—DCCI21—
coupling, either in the presence or absence of the N,N-di-
methyl-4-pyridinamine (DMAP) acylation catalyst,27 was
successfully employed. Whenever the DCCI coupling did
not occur as expected, alternative strategies such as the
Ph3P/CCl4,
24 the HBTU/DIEA22,23 or the HBTU/HOBt/
DIEA26 methods were also tested. N a-protected amino
acids or dipeptides were employed in the condensation
steps.
N 4-Acetylsulfamethazine as well as N 1-, N 1,N 4- and N 4-
acetylsulfisoxazoles had been previously synthesized,30 – 34
thus reported methods were employed for their preparation;
target compounds were successfully obtained in high yields,
and possessed the correct physical and chemical properties
(melting points, 1H and 13C NMR chemical shifts,
molecular weights and elemental analyses—data not
shown).
4.2. Sulfonamide acylation with N a-protected amino
acids or dipeptides
4.2.1. N 4-BocGlySulfamethazine (5a). To a stirred
solution of N a-BocGlycine (2.0 mmol) in dry tetrahydro-
furan (THF) was carefully added DCCI (2.2 mmol) at 08C,
followed by DMAP (0.2 mmol) and sulfamethazine
(2.0 mmol); the mixture was stirred at 08C for 1 h and
then at room temperature for one day; the insoluble
dicyclohexylurea (DCU) was removed by suction filtration
and, after THF evaporation, warm acetone was added to the
oily residue; the solution was allowed to stand at 48C
overnight and additional DCU was precipitated and
removed by filtration; the filtrate was vacuum dried and
the viscous oil obtained was then eluted on a silica-gel
column, using dichloromethane (DCM)/Acetone 5:1 (v/v);
fractions containing pure product were pooled and evapor-
ated to dryness; the resulting white solid (52%) was
recrystallized from chloroform (mp 182–1848C). dH
(DMSO-d6), 11.62 (bs, 1H), 10.31 (s, 1H), 7.94 (d,
J¼8.7 Hz, 2H), 7.73 (d, J¼8.7 Hz, 2H), 7.11 (t, J¼6.0 Hz,
1H), 6.75 (s, 1H), 3.74 (d, J¼6.0 Hz, 2H), 2.25 (s, 6H), 1.39
(s, 9H); dC (DMSO-d6), 168.8, 168.4, 156.1, 155.9, 134.3,
129.3, 117.9, 113.4, 78.0, 43.8, 28.1, 22.8. Anal. calcd for
C19H25N5O5S (435.5): C, 52.40; H, 5.79; N, 16.08; S,
7.36%. Found: C, 52.16; H, 5.90; N, 15.67; S, 7.18%.
4.2.2. N 4-ZGlySulfamethazine (6a). The synthesis pro-
cedure was exactly the same as described for compound 5a,
with the exception that the condensation with ZGlyOH was
allowed to proceed at room temperature for two days; after
complete removal of DCU and solvent evaporation, the
resulting mixture was eluted on silica with DCM/Acetone
3:1 (v/v); fractions containing pure product were pooled and
evaporated to dryness; the resulting white solid (41%) was
recrystallized from ethanol (mp 195–1978C). dH (DMSO-
d6), 11.63 (bs, 1H), 10.36 (s, 1H), 7.94 (d, J¼8.7 Hz, 2H),
7.73 (d, J¼8.7 Hz, 2H), 7.62 (t, J¼6.0 Hz, 1H), 7.38 (m,
5H), 6.75 (s, 1H), 5.05 (s, 2H), 3.83 (d, J¼6.0 Hz, 2H), 2.25
(s, 6H); dC (DMSO-d6), 168.6, 168.2, 156.5, 156.1, 142.4,
136.9, 134.4, 129.3, 128.3, 127.7, 127.6, 117.9, 113.5, 65.4,
44.1, 22.8. Anal. calcd for C22H23N5O5S (469.5): C, 56.28;
H, 4.94; N, 14.92; S, 6.83%. Found: C, 56.30; H, 4.98; N,
14.80; S, 6.80%.
4.2.3. N 4-BocAlaSulfamethazine (7a). The synthesis and
crude mixture work-up were done as for 5a, with
BocAlaOH as the amino acid component; the product was
isolated by elution on a silica column with DCM/
Acetonitrile (ACN) 2:1 (v/v); fractions containing only the
new product were pooled and solvent evaporated under
reduced pressure; the resulting white solid (49%) was
recrystallized from 1:5 (v/v) DCM/ACN (mp 205–2068C).
dH (DMSO-d6), 11.63 (bs, 1H), 10.32 (s, 1H), 7.94 (d,
J¼8.4 Hz, 2H), 7.75 (d, J¼8.4 Hz, 2H), 7.18 (d, J¼6.3 Hz,
1H), 6.75 (s, 1H), 4.11 (m, 1H), 2.25 (s, 6H), 1.37 (s, 9H),
1.25 (d, J¼6.0 Hz, 3H); dC (DMSO-d6), 172.6, 168.3, 156.2,
155.2, 142.7, 134.1, 129.3, 118.1, 113.3, 78.1, 50.6, 28.2,
23.0, 17.7. Anal. calcd for C20H27N5O5S·1/2H2O (458.5): C,
52.39; H, 6.15; N, 15.27; S, 6.99%. Found: C, 52.57; H,
6.08; N, 15.22; S, 6.70%.
4.2.4. N 4-BocPheSulfamethazine (8a). The condensation
of sulfamethazine with BocPheOH was done as described
for 5a; the crude mixture was then eluted on silica with
DCM/ACN 4:1 (v/v), and the product isolated as a white
solid (56%), which was recrystallized from ACN (mp 198–
2008C). dH (DMSO-d6), 11.61 (bs, 1H), 10.42 (s, 1H), 7.95
(d, J¼8.4 Hz, 2H), 7.74 (d, J¼8.4 Hz, 2H), 7.26 (m, 6H),
6.77 (s, 1H), 4.30 (m, 1H), 2.97 (dd, J¼3.4, 15.2 Hz, 1H),
2.83 (dd, J¼3.3, 15.3 Hz, 1H), 2.26 (s, 6H), 1.32 (s, 9H); dC
(DMSO-d6), 171.6, 167.7, 156.2, 155.4, 142.5, 137.8, 134.6,
129.4, 129.3, 128.1, 126.4, 118.3, 113.9, 78.2, 56.8, 37.2,
28.2, 23.0. Anal. calcd for C26H31N5O5S·1/2H2O (534.6): C,
58.41; H, 6.03; N, 13.10; S, 6.00%. Found: C, 58.50; H,
5.80; N, 12.90; S, 6.04%.
4.2.5. N 4-BocGlyGlySulfamethazine (9a). The synthesis
reaction and work-up were performed as described for 5a,
using BocGlyGlyOH as the acylating agent; the product was
isolated after elution on silica with DCM/Acetone 1:1 (v/v),
as a white solid (20%), which was recrystallized from
ethanol (mp 220–2218C). dH (DMSO-d6), 11.63 (bs, 1H),
10.22 (s, 1H), 8.22 (t, J¼5.4 Hz, 1H), 7.95 (d, J¼8.4 Hz,
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2H), 7.75 (d, J¼8.4 Hz, 2H), 7.11 (d, J¼5.7 Hz, 1H), 6.75
(s, 1H), 3.92 (d, J¼5.4 Hz, 2H), 3.61 (d, J¼5.7 Hz, 2H),
2.24 (s, 6H), 1.38 (s, 9H); dC (DMSO-d6), 170.0, 168.4,
167.9, 156.2, 156.0, 142.4, 134.6, 129.4, 118.1, 113.5, 78.2,
43.3, 42.8, 28.2, 22.9. Anal. calcd for C21H28N6O6S·1/2H2O
(501.6): C, 50.29; H, 5.83; N, 16.76; S, 6.39%. Found: C,
50.40; H, 5.60; N, 16.50; S, 6.50%.
4.2.6. N 4-BocAlaGlySulfamethazine (10a). Both the
synthesis and DCU precipitation were as described for 5a,
with BocAlaGlyOH as the acyl component; the reaction
mixture was eluted on silica with DCM/Acetone 2:1 (v/v),
and the product was isolated as a white solid (26%), which
was recrystallized from ACN (mp 204–2068C). dH (DMSO-
d6), 11.55 (bs, 1H), 10.11 (s, 1H), 8.25 (m, 1H), 7.93 (d, J¼
8.1 Hz, 2H), 7.75 (d, J¼8.1 Hz, 2H), 7.12 (d, J¼6.3 Hz,
1H), 6.76 (s, 1H), 3.98 (m, 1H), 3.88 (d, J¼5.4 Hz, 2H),
2.24 (s, 6H), 1.37 (s, 9H), 1.20 (d, J¼7.2 Hz, 3H); dC
(DMSO-d6), 173.4, 168.4, 167.5, 156.2, 155.4, 142.3, 134.7,
129.4, 118.1, 113.5, 78.3, 49.9, 42.9, 28.2, 22.9, 18.0. Anal.
calcd for C22H30N6O6S (506.6): C, 52.16; H, 5.97; N, 16.59;
S, 6.33%. Found: C, 52.28; H, 6.02; N, 16.60; S, 6.03%.
4.2.7. N 4-BocPheGlySulfamethazine (11a). The synthesis
reaction and DCU filtration were performed as previously
explained for 5a, using BocPheGlyOH as acylating agent;
the crude mixture was then eluted on silica with DCM/ACN
2:1 (v/v), and the product was isolated as a white solid
(27%), which was recrystallized from ACN (mp 194–
1958C). dH (DMSO-d6), 11.62 (bs, 1H), 10.23 (s, 1H), 8.40
(m, 1H), 7.94 (d, J¼8.2 Hz, 2H), 7.75 (d, J¼8.2 Hz, 2H),
7.28 (m, 5H), 7.05 (d, J¼8.1 Hz, 1H), 6.76 (s, 1H), 4.20 (m,
1H), 3.94 (m, 2H), 3.03 (dd, J¼4.9 Hz, 13.9 Hz, 1H), 2.74
(dd, J¼6.0 Hz, 13.8 Hz, 1H), 2.25 (s, 6H), 1.28 (s, 9H); dC
(DMSO-d6), 172.4, 168.4, 167.3, 156.2, 155.5, 142.4, 138.3,
134.7, 129.4, 129.2, 128.1, 126.2, 118.1, 113.6, 78.2, 55.8,
42.9, 37.4, 28.1, 22.9. Anal. calcd for C28H34N6O6S (582.7):
C, 57.72; H, 5.88; N, 14.42; S, 5.50%. Found: C, 57.80; H,
5.94; N, 14.30; S, 5.24%.
4.2.8. N 4-BocGlySulfadimethoxine (5b). To a stirred
solution of BocGlyOH (2.0 mmol) in dry THF was carefully
added DCCI (2.2 mmol) at 08C, followed by sulfadimethox-
ine (2.0 mmol); the mixture was stirred at 08C for one hour
and then at room temperature for two days; DCU was
removed by suction filtration and, after THF evaporation,
warm acetone was added to the residue; the solution was
allowed to stand at 48C overnight and precipitated DCU was
removed by filtration; the filtrate was evaporated to dryness
and the yellowish solid obtained was then eluted on a
silica-gel column, using DCM/Acetone 5:1 (v/v); fractions
containing pure product were pooled and evaporated to
dryness, giving a yellowish solid (41%) with mp 193–
1958C. dH (CDCl3), 9.28 (s, 1H), 7.73 (d, J¼8.1 Hz, 2H),
7.54 (d, J¼8.1 Hz, 2H), 6.23 (s, 1H), 5.79 (m, 1H), 4.02 (d,
J¼5.8 Hz, 2H), 3.89 (s, 3H), 3.86 (s, 3H), 1.45 (s, 9H); dC
(CDCl3), 172.6, 169.0, 164.1, 159.2, 156.8, 142.3, 134.0,
128.4, 119.4, 85.7, 80.8, 54.8, 54.2, 45.2, 28.2. m/z (467.50):
468.38 (MHþ).
4.2.9. N 4-BocGlyGlySulfadimethoxine (6b). The pro-
cedure to react sulfadimethoxine with BocGlyGlyOH was
as described for 5b, but in this case reaction was allowed to
proceed for four days and DCU was precipitated from THF
instead of acetone; the crude mixture was eluted on a silica-
gel column, using DCM/THF 4:1 (v/v); fractions containing
pure product were pooled and evaporated to dryness, giving
a white solid (55%) with mp 223–2248C. dH (DMSO-d6),
10.29 (s, 1H), 8.19 (t, J¼5.4 Hz, 1H), 7.87 (d, J¼8.9 Hz,
2H), 7.76 (d, J¼8.9 Hz, 2H), 7.07 (t, J¼5.9 Hz, 1H), 5.91 (s,
1H), 3.90 (d, J¼5.5 Hz, 2H), 3.77 (s, 3H), 3.73 (s, 3H), 3.58
(d, J¼6.2 Hz, 2H), 1.35 (s, 9H); dC (DMSO-d6), 171.7,
170.1, 168.5, 164.3, 160.0, 156.0, 143.0, 133.8, 128.6,
118.8, 84.6, 78.3, 54.6, 53.9, 43.3, 42.8, 28.2. m/z (524.55):
525.43 (MHþ).
4.2.10. N 4-BocAlaGlySulfadimethoxine (7b). The syn-
thesis was performed as described for 6b, using BocAla
GlyOH as acyl component; the crude mixture was eluted
on a silica-gel column, using DCM/THF 4:1 (v/v);
fractions containing pure product were pooled and
evaporated to dryness, resulting a yellowish solid (56%)
with mp 117–1188C. dH (DMSO-d6), 10.16 (s, 1H), 8.25
(m, 1H), 7.87 (d, J¼8.5 Hz, 2H), 7.76 (d, J¼8.5 Hz, 2H),
7.09 (d, J¼6.8 Hz, 1H), 5.91 (s, 1H), 3.96 (q, J¼7.1 Hz,
1H), 3.88 (d, J¼ 5.3 Hz, 2H), 3.76 (s, 3H), 3.72 (s, 3H),
1.33 (s, 9H), 1.18 (d, J¼7.1 Hz, 3H); dC (DMSO-d6),
173.6, 171.6, 166.6, 164.4, 160.0, 155.6, 143.0, 133.9,
128.7, 118.9, 84.7, 78.5, 54.7, 54.0, 50.0, 43.0, 28.3, 16.0.
m/z (538.58): 538.99 (MHþ).
4.2.11. N 4-BocPheGlySulfadimethoxine (8b). The syn-
thesis was performed as described for 6b, using BocPhe
GlyOH as acylating agent; the crude mixture was eluted on
a silica-gel column, using DCM/Acetone 8:1 (v/v); fractions
containing pure product were pooled and evaporated to
dryness, resulting a yellowish solid (52%) with mp 186–
1878C. dH (DMSO-d6), 10.28 (s, 1H), 8.38 (t, J¼5.5 Hz,
1H), 7.88 (d, J¼9.0 Hz, 2H), 7.77 (d, J¼9.0 Hz, 2H), 7.20
(m, 5H), 7.03 (d, J¼8.3 Hz, 1H), 5.92 (s, 1H), 4.20 (m, 1H),
3.92 (d, J¼5.4 Hz, 2H), 3.77 (s, 3H), 3.73 (s, 3H), 2.98 (dd,
J¼4.0 Hz, 13.8 Hz, 1H), 2.77 (dd, J¼10.5 Hz, 13.5 Hz,
1H), 1.34 (s, 9H); dC (DMSO-d6), 172.4, 171.7, 166.4,
164.3, 160.1, 155.5, 142.9, 138.2, 133.8, 129.2, 128.6,
128.1, 126.2, 118.8, 84.6, 78.2, 55.8, 54.6, 53.8, 42.9, 37.4,
28.3. m/z (614.68): 615.49 (MHþ).
4.2.12. N 4-BocGlySulfamethoxypyridazine (5c). To a
stirred solution of BocGlyOH (2.0 mmol) in dry THF
was carefully added DCCI (2.2 mmol) at 08C, followed
by sulfamethoxypyridazine (2.0 mmol); the mixture was
stirred at 08C for 1 h and then at room temperature for two
days; DCU was removed by suction filtration and, after THF
evaporation, warm acetone was added to the residue; the
solution was allowed to stand at 48C overnight and
precipitated DCU was removed by filtration; the filtrate
was evaporated to dryness and the yellowish solid obtained
was then eluted on a silica-gel column, using DCM/Acetone
5:1 (v/v); fractions containing pure product were pooled and
evaporated to dryness, giving a yellowish solid (43%) with
mp 105–1078C. dH (DMSO-d6), 10.29 (s, 1H), 7.77 (d, J¼
8.9 Hz, 2H), 7.70 (d, J¼9.8 Hz, 1H), 7.69 (d, J¼8.9 Hz,
2H), 7.34 (d, J¼9.8 Hz, 1H), 7.10 (t, J¼6.0 Hz, 1H), 3.80 (s,
3H), 3.70 (d, J¼6.0 Hz, 2H), 1.36 (s, 9H); dC (DMSO-d6),
168.9, 156.0, 153.0, 142.1, 127.4, 118.7, 78.2, 54.6, 43.9,
28.2. m/z (437.47): 438.13 (MHþ).
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4.2.13. N 4-BocGlyGlySulfamethoxypyridazine (6c). The
procedure to react sulfamethoxypyridazine with BocGly
GlyOH was as described for 5c; the crude mixture was
eluted on a silica-gel column, using DCM/THF 1:1 (v/v);
fractions containing pure product were pooled and evapo-
rated to dryness, giving a white solid (37%) with mp 189–
1918C. dH (DMSO-d6), 10.20 (s, 1H), 8.19 (m, 1H), 7.78 (d,
J¼8.7 Hz, 2H), 7.70 (d, J¼9.8 Hz, 1H), 7.69 (d, J¼8.7 Hz,
2H), 7.34 (d, J¼9.8 Hz, 1H), 7.07 (m, 1H), 3.90 (d, J¼
5.1 Hz, 2H), 3.60 (s, 3H), 3.59 (d, J¼5.7 Hz, 2H), 1.35 (s,
9H); dC (DMSO-d6), 170.0, 168.3, 156.0, 142.0, 127.4,
126.3, 125.1, 118.8, 78.2, 54.5, 43.3, 42.8, 28.2. m/z
(494.52): 495.14 (MHþ).
4.2.14. N 4-BocAlaGlySulfamethoxypyridazine (7c). The
synthesis was performed as described for 5c, using
BocAlaGlyOH as the acyl component. The crude mixture
was eluted on a silica-gel column, using DCM/Acetone 4:1
(v/v); fractions containing pure product were pooled and
evaporated to dryness, yielding a yellowish solid (60%) with
mp 122–1258C. dH (DMSO-d6), 10.10 (s, 1H), 8.23 (t, J¼
5.5 Hz, 1H), 7.78 (d, J¼9.1 Hz, 2H), 7.72 (d, J¼9.1 Hz,
2H), 7.71 (d, J¼9.8 Hz, 1H), 7.34 (d, J¼9.8 Hz, 1H), 7.09
(d, J¼6.8 Hz, 1H), 3.96 (q, J¼7.0 Hz, 3H), 3.88 (d, J¼
5.4 Hz, 2H), 3.81 (s, 3H), 1.35 (s, 9H); dC (DMSO-d6),
173.4, 168.3, 155.4, 152.9, 141.9, 127.4, 126.2, 118.8, 78.3,
54.5, 49.9, 42.8, 28.2, 17.9. m/z (508.55): 508.98 (MHþ).
4.2.15. N 4-BocPheGlySulfamethoxypyridazine (8c). The
synthesis was performed as described for 5c, using
BocPheGlyOH as acylating agent; the crude mixture was
eluted on a silica-gel column, using DCM/Acetone 4:1
(v/v); fractions containing pure product were pooled and
evaporated to dryness, yielding a yellowish solid (52%)
with mp 125–1288C. dH (DMSO-d6), 10.21 (s, 1H), 8.37 (t,
J¼5.5 Hz, 1H), 7.78 (d, J¼9.0 Hz, 2H), 7.72 (d, J¼9.0 Hz,
2H), 7.71 (d, J¼9.9 Hz, 1H), 7.34 (d, J¼9.9 Hz, 1H), 7.20
(m, 5H), 7.02 (d, J¼8.3 Hz, 1H), 4.20 (m, 1H), 3.92 (d,
J¼5.1 Hz, 2H), 3.81 (s, 3H), 3.05 (dd, J¼3.8, 13.7 Hz, 3H),
2.74 (dd, J¼11.0, 14.0 Hz, 1H), 1.26 (s, 9H); dC (DMSO-
d6), 172.4, 168.3, 155.5, 153.0, 142.0, 138.2, 129.3, 128.1,
127.5, 126.3, 118.8, 78.3, 55.9, 54.6, 42.9, 37.4, 28.2. m/z
(584.65): 585.72 (MHþ).
4.2.16. N 1-ZGlySulfisoxazole (5d). The synthesis pro-
cedure was exactly the same as described for compound 6a,
replacing sulfamethazine by sulfisoxazole; the crude
mixture was eluted on silica with DCM/Acetone 10:1
(v/v); fractions containing the major product (somewhat
contaminated) were pooled and evaporated to dryness; the
resulting yellowish solid (8%) was identified as N 1-
ZGlySulfisoxazole by NMR spectroscopy. dH (DMSO-d6),
7.62 (d, J¼ 8.7 Hz, 2H), 7.55 (t, J¼6.0 Hz, 1H), 7.34 (m, 5H),
6.68 (d, J¼8.7 Hz, 2H), 6.54 (s, 2H), 5.01 (s, 2H), 3.52 (d, J¼
6.0 Hz, 2H), 2.26 (s, 3H), 1.90 (s, 3H); dC (DMSO-d6), 168.8,
160.2, 156.8, 156.2, 153.7, 136.9, 128.8, 124.4, 128.3, 127.7,
127.6, 112.8, 104.6, 65.3, 44.2, 10.3, 5.8. Anal. calcd for
C21H22N4O6S (458.5): C, 55.01; H, 4.84; N, 12.22; S, 6.99%.
Found: C, 54.77; H, 4.78; N, 11.70; S, 6.80%.
4.3. Computational details
Semi-empirical and density functional calculations have
been carried out by employing the GAMESS-US suite of
programs.35 The semi-empirical calculations at the PM3
level of theory were performed to study extensively all
relevant conformations of both sulfonamide and corre-
sponding products of acylation by amino acids. Density
functional theory (DFT) calculations within the Kohn–
Sham formalism were carried out using the B3LYP three-
parameter hybrid method proposed by Becke.36 This
approach comprises an exchange-correlation functional
that mixes the non-local Fock exchange with the gradient-
corrected form of Becke37 and adds the correlation
functional proposed by Lee et al.38
Different basis sets were used to describe the atomic
electron density and all-electrons have been explicitly
included in the calculations. For the most stable confor-
mations, B3LYP full-optimization of geometry and analyti-
cal calculation of vibrational frequencies were carried out
employing the 6-31G* basis set,39 with one d polarization
function. Single-point runs were also performed at the
optimized geometries using the B3LYP/6-311þG**
approach.39 The present approach is known to generate
very good optimized structures and also accurate thermo-
chemical data.40 These calculations have been performed
using the GAMESS-US package.
Frequencies were computed for all optimized species in
order to characterize each stationary point as a minimum
and to correct computed electronic energy values for Zero-
Point Energies, ZPE, as well as translational, rotational and
vibrational contributions to the enthalpy at T¼298.15 K. As
suggested by Scott et al.,41 ZPE values were scaled by a
factor of 0.9804 which was introduced in the calculation of
frequencies.
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